Status:
WITHDRAWN
Candesartan as an Adjunctive Treatment for Bipolar Depression
Lead Sponsor:
The University of Texas Health Science Center, Houston
Conditions:
Bipolar Disorder Depression
Eligibility:
All Genders
18-65 years
Phase:
EARLY_PHASE1
Brief Summary
This study will assess the safety and tolerability of Candesartan when used in patients with Bipolar Disorder, in addition to their medication treatment.
Detailed Description
Pharmacological options for the treatment of Bipolar disorder (BD) are limited and a large proportion of patients does not show adequate response to treatment, especially in the case of bipolar depres...
Eligibility Criteria
Inclusion
- A diagnosis of BD type I or II, and currently in a depressive episode, based on DSM-5 criteria.
- Inclusion criteria:
- Age 18 to 65 years.
- A diagnosis of BD type I or II according to DSM-5 criteria, established through the administration of the MINI.
- Currently in a depressive episode, based on DSM-5 criteria.
- MADRS \>20 at entry in the study.
- No history of hypertension, diabetes, stroke, liver, kidney, heart disease, bleeding disorders, cancer, hypothyroidism, auto-immune diseases, and any brain disorder (seizure disorder, stroke, dementia, or neurodegenerative diseases), as well as other conditions that could impact patient's safety associated with participation in the study.
- On therapeutic doses of a mood stabilizing drug (anticonvulsants or atypical antipsychotics, but not lithium) or combinations of medications (including antidepressants, as long as receiving at least one mood stabilizing agent) for at least two weeks.
- Allowed psychiatric comorbid conditions, such as anxiety disorders, PTSD and past history of substance use (as long as do NOT meet abuse or dependence criteria according to the SCID-I in the past 2 months).
- Exclusion criteria:
- Current use of angiotensin receptor antagonists, angiotensin converting enzyme inhibitors. (ACE inhibitors), or a history of allergies or poor tolerability to those medications
- Current use of lithium or any other medications that could implicate in potentially dangerous. interactions with candesartan, based on available literature and the investigator's judgement.
- Pregnancy or current breastfeeding.
- Acute systemic infections or other acute medical conditions at the time of study entry.
- Acute suicidal or homicidal ideation or other imminent concerns about safety, based on the investigator's judgement and/or on a score equal or higher than 4 in the item 10 of the MADRS.
- Family history of hereditary neurologic disorder.
- Unable to give informed consent for any reason.
- Floating metallic objects in the body.
- Positive urine drug screening at the time of study entry.
- Current or previous diagnosis of intellectual disability, learning disability, or other severe neurodevelopmental disorders.
- History of traumatic brain injury or head trauma with loss of consciousness for more than 30 minutes.
Exclusion
Key Trial Info
Start Date :
October 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04430959
Start Date
October 1 2020
End Date
September 1 2022
Last Update
April 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Texas Health Science Center at Houston
Houston, Texas, United States, 77030